BioCentury
ARTICLE | Financial News

Acambis reports earnings

March 9, 2005 2:30 AM UTC

Acambis (LSE:ACM; ACAM) reported fourth quarter and full year 2004 earnings and hinted that in 2005, it may sacrifice profitability in favor of R&D investment. The company also said that a BLA for its Arilvax yellow fever vaccine will not be submitted during this half as was previously planned.

For the fourth quarter, ACM reported EPS of 4.7p, up from a 0.8p loss in the same period in 2003. Fourth quarter revenues were L23.1 million ($44.4 million), up 10% from L21 million in the fourth quarter of 2003. ...